Beef calf Indemnity rates updated for 2023 by FSA

Aug 30, 2023

A recent announcement from the U.S. Department of Agriculture’s Farm Service Agency (FSA) shed light on modifications in the Livestock Indemnity Program (LIP) for 2023. The beef calves, particularly those over 800 pounds, will now receive an increased indemnity rate of $1618 per head, up from the previous $1244.

What’s notable is the retroactive application of this new rate. Losses from January 1, 2023, will benefit from this hike without necessitating any separate formalities from the producers.

With these changes in place, the FSA projects to initiate payments for current losses by the upcoming week. They've also acknowledged potential weight losses in livestock due to extreme weather, assuring producers of a plan to address such situations.

The FSA’s vision for LIP emphasizes its adaptability to live market conditions for future payment rate determinations.

Justin Tupper, the President of the U.S. Cattlemen’s Association, praised the timely decision by the FSA. He underscored the importance of these changes in representing the genuine market value of the animals and expressed appreciation for FSA’s support, especially from the local offices during these challenging times.

Source : wisconsinagconnection

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.